Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-09-21-Speech-2-509"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20100921.18.2-509"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Mr President, ladies and gentlemen, if we look back at how we began discussing this problem last year in the last parliamentary term, we can only be full of admiration for the achievements of the rapporteurs. What they have achieved by bringing the process to a conclusion after the first reading is excellent. Well done! This is an important instrument, as many people have already said today. I was most surprised by the fact that the Member States agreed without objection to establishing a database with links across Europe.
I would like to make one additional point. We should make better use of the opportunities provided by the European Medicines Agency and the EudraVigilance database, and I am calling on the Commission to do this, in order to improve and promote the quality of healthcare and the quality of products in Europe. This is an important step in the right direction.
However, I do not want to see too much attention being paid to reports from individual citizens about side effects. We should ensure that this does not happen. The reports should only be included in the database when they have been submitted for an expert investigation. Just because someone criticises a product, this does not necessarily give them the right to have their criticism documented in the database."@en1
|
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples